Melanotan II vs PT-141 (Bremelanotide)
Updated July 21, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of Melanotan II and PT-141 (Bremelanotide) (also searched as PT-141 (Bremelanotide) vs Melanotan II) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
Melanotan II centers on skin, while PT-141 (Bremelanotide) leans toward neuro. On indexed research, Melanotan II is ahead (Melanotan II: 4 studies, Preclinical; PT-141 (Bremelanotide): 4, Preclinical). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •Melanotan II is strongest for skin; PT-141 (Bremelanotide) for neuro.
- •Evidence: Melanotan II Preclinical (4 studies) vs PT-141 (Bremelanotide) Preclinical (4).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
Synthetic Melanocortin Peptide | Tanning & Sexual Function
Melanotan II vs PT-141 (Bremelanotide): side-by-side
| Metric | Melanotan II | PT-141 (Bremelanotide) |
|---|---|---|
| Class | Skin | — |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Preclinical | Preclinical |
| Studies indexed | 4 | 4 |
| Research level | Well Studied | — |
| Strongest effect | Skin & aesthetics | Neuro & mood |
| Healing & recovery | 1.0▲ | 0.0 |
| Muscle & body comp | 0.0 | 0.0 |
| Metabolic & appetite | 0.0 | 0.0 |
| Neuro & mood | 2.0 | 4.0▲ |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 0.0 | 0.0 |
| Skin & aesthetics | 4.0▲ | 0.0 |
▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).
Mechanism & pharmacokinetics
| Property | Melanotan II | PT-141 (Bremelanotide) |
|---|---|---|
| Mechanism | Melanocortin-receptor agonist | — |
| Route | Subcutaneous injection (research use) | — |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is Melanotan II?
### Summary Melanotan II is a synthetic analog of the naturally occurring peptide hormone alpha-melanocyte-stimulating hormone (α-MSH), primarily studied for its effects on skin pigmentation and potential therapeutic applications. Research has also explored its impact on mood and stress responses, though caution is advised due to potential side effects and safety concerns.
Full Melanotan II profile, mechanism & studies →What is PT-141 (Bremelanotide)?
### Summary PT-141 (Bremelanotide) is a synthetic peptide that acts as a melanocortin receptor agonist, primarily investigated for its potential to treat sexual dysfunction, particularly in women experiencing hypoactive sexual desire disorder. Its mechanism of action involves the modulation of pathways related to sexual arousal and desire.
Full PT-141 (Bremelanotide) profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | Melanotan II | 1.0/5 effect signal |
| Neuro | PT-141 (Bremelanotide) | 4.0/5 effect signal |
| Skin | Melanotan II | 4.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack Melanotan II and PT-141 (Bremelanotide)?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
Melanotan II vs PT-141 (Bremelanotide): side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
Melanotan II has 4 approved studies indexed (Preclinical), and PT-141 (Bremelanotide) has 4 (Preclinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is Melanotan II or PT-141 (Bremelanotide) better?
It depends on your goal. Melanotan II is strongest for skin; PT-141 (Bremelanotide) for neuro. Melanotan II has more indexed studies (4). See the goal-by-goal breakdown above.
Which has more research, Melanotan II or PT-141 (Bremelanotide)?
Melanotan II has 4 approved studies indexed (Preclinical); PT-141 (Bremelanotide) has 4 (Preclinical). Higher counts mean more to read, not proven superiority.
Can you stack Melanotan II and PT-141 (Bremelanotide)?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of Melanotan II vs PT-141 (Bremelanotide)?
Melanotan II: no community-reported effects logged yet. PT-141 (Bremelanotide): none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is Melanotan II or PT-141 (Bremelanotide) FDA-approved?
Melanotan II is a research-use compound and is not FDA-approved. PT-141 (Bremelanotide) is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is PT-141 (Bremelanotide) better than Melanotan II?
For neuro, PT-141 (Bremelanotide) has the edge; for skin, Melanotan II does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Melanotan II and PT-141 (Bremelanotide) are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 21, 2026.